Sleuth checks every value from 150 million+ documents as they come in, links it to its drug, trial, or company, and scores its sourcing. You see where each number came from and the handful to check.
Sleuth scores every value in a dataset with the same rules: how good its best source is, whether independent sources agree, and, where it matters, how recent it is. Most score high, and you can trust them. Review mode puts the low scores in front of you, so you can check each one.
Ask Claude on its own and it rebuilds the landscape from a web search every time. Sleuth has already matched every trial, drug, company, and deal to one record and linked them, so your answer starts from that work.
63%
more of the landscape found with Sleuth connected, on average across 15 tests
+55%
Claude
+27%
ChatGPT
+108%
Perplexity
Sleuth takes in new documents every day and runs each one through the same matching and checks before it reaches your datasets, so the knowledge base stays clean and current.
MK-3475, lambrolizumab, and Keytruda are all pembrolizumab. Every code name, old name, and typo resolves to one record.
When ClinicalTrials.gov and China’s registry disagree about a trial, Sleuth keeps both sources and shows you the conflict in Review mode.
An abstract reports the result, the comparison arm, and the hazard ratio. Sleuth’s knowledge base knows the difference, and pulls what’s relevant.
Lung adenocarcinoma sits under NSCLC, which sits under lung cancer. Ask about lung cancer, and the narrower programs show up.
Sleuth keeps earlier versions of company pipeline pages, so a program dropped without a press release shows up as a change, not a silence.
Every value is dated. Where recency matters, a status last updated years ago scores lower than one updated this month.

“The genetic basis is always the thing that takes the longest, and the public data on it is often wishy-washy. Sleuth told us how sure we could be about every value, with the reasoning and the sources. It made it easy to find what I needed, and to know what to double-check before anything went to our board.”

Dr. John Lambourne
Gene editing lead, Pencil Biosciences
The values to review stand out at a glance
Review first
Values Sleuth flagged for conflicting sources or thin evidence, where John’s expertise mattered most
Use as is
Well-sourced values John could use without a deep review
On Enterprise, your documents and data go into the knowledge base next to Sleuth’s, held to the same standard and kept private.
Bring in documents and data from Drive, SharePoint, Box, or your warehouse. Sleuth matches your internal program names to the same records and checks them the same way, so your programs show up in the same tables as everyone else’s.
Sleuth has a SOC 2 Type II report and encrypts your data in transit and at rest. Your company’s questions, documents, and results are never shown in anyone else’s work. A single-tenant option gives you your own environment.